Menu Search
Equities

Inmode Ltd

INMD:NSQ

Inmode Ltd

Actions
Health CareMedical Equipment and Services
  • Price (USD)17.69
  • Today's Change-0.05 / -0.28%
  • Shares traded239.00k
  • 1 Year change-46.51%
  • Beta2.1750
Data delayed at least 15 minutes, as of Sep 20 2024 15:22 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Inmode Ltd grew revenues 8.32% from 454.27m to 492.05m while net income improved 22.54% from 161.52m to 197.92m.
Gross margin82.27%
Net profit margin35.81%
Operating margin32.18%
Return on assets18.72%
Return on equity21.05%
Return on investment20.79%
More ▼

Cash flow in USDView more

In 2023, Inmode Ltd increased its cash reserves by 48.05%, or 46.87m. The company earned 176.83m from its operations for a Cash Flow Margin of 35.94%. In addition the company generated 5.50m cash from financing while 136.06m was spent on investing.
Cash flow per share1.74
Price/Cash flow per share9.03
Book value per share9.09
Tangible book value per share9.09
More ▼

Balance sheet in USDView more

Inmode Ltd appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio8.63
Quick ratio8.09
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items increased 21.75%. Additionally, five year annualized earnings per share growth ranks above the industry average relative to its peers.
EPS growth(5 years)45.75
EPS (TTM) vs
TTM 1 year ago		-18.93
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.